AAA
CLDX icon

Affinity Asset Advisors’s Celldex Therapeutics CLDX Stock Holding History

Affinity Asset Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-145,000
Closed -$3.91M – 66
2022
Q2 		$3.91M Buy
+145,000
New +$4.21M 1.65% 26

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Affinity Asset Advisors's CLDX Position: Q2 2026 in Review

Affinity Asset Advisors increased its Celldex Therapeutics (CLDX) stake by 40% in Q2 2026, buying an estimated $6.46M and bringing the position to 700,000 shares worth $26M. The position accounts for 1.18% of the portfolio, ranked #25.

Affinity Asset Advisors first reported a position in CLDX in Q4 2020 and has held it in 21 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Affinity Asset Advisors held 700,000 shares of Celldex Therapeutics worth $26M as of Q2 2026.
  • Affinity Asset Advisors bought 200,000 Celldex Therapeutics shares in Q2 2026, an estimated $6.46M.
  • Celldex Therapeutics made up 1.18% of Affinity Asset Advisors's portfolio in Q2 2026, its #25 holding.
  • Affinity Asset Advisors first reported a position in Celldex Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.